fluconazole has been researched along with oseltamivir in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aytemir, MD; Ozçelik, B | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Balzarini, J; De Clercq, E; Karki, SS; Kulkarni, AA; Kumar, S; Veliyath, SK | 1 |
1 review(s) available for fluconazole and oseltamivir
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 other study(ies) available for fluconazole and oseltamivir
| Article | Year |
|---|---|
A study of cytotoxicity of novel chlorokojic acid derivatives with their antimicrobial and antiviral activities.
Topics: Animals; Anti-Infective Agents; Antiviral Agents; Bacteria; Cell Line; Chlorocebus aethiops; Drug Evaluation, Preclinical; Fungi; Herpesvirus 1, Human; Mannich Bases; Microbial Sensitivity Tests; Parainfluenza Virus 3, Human; Pyrones; Spectrum Analysis; Vero Cells | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-
Topics: | 2013 |